Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cellectis SA
CLLSCurrent price
1.55 USD
-0.02 USD (-1.27%)
Last closed
1.46 USD
Company
www.cellectis.com
ISIN
US15117K1034
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
146 423 408 USD
Yield for 12 month
-47.81 %
1Y
3Y
5Y
10Y
15Y
CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8 rue de la Croix Jarry, Paris, France, 75013
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.60 USDP/E ratio
–Dividend Yield
–Current Year
+41 506 000 USD
Last Year
+755 000 USD
Current Quarter
+10 655 000 USD
Last Quarter
+12 717 000 USD
Current Year
+21 631 000 USD
Last Year
+18 000 USD
Current Quarter
+8 640 000 USD
Last Quarter
+6 887 000 USD
Key Figures CLLS
1 year
3 years
5 years
10 years
EBITDA
-48 252 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-10.37 %
PEG Ratio
–
Return On Equity TTM
-34.08 %
Wall Street Target Price
5.60 USD
Revenue TTM
49 217 000 USD
Book Value
1.82 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
662.10 %
Dividend Yield
–
Gross Profit TTM
49 217 000 USD
Earnings per share
-0.67 USD
Diluted Eps TTM
-0.67 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
-74.69 %
Dividend Analytics CLLS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CLLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation CLLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.78
Price Sales TTM
2.98
Enterprise Value EBITDA
-3.90
Price Book MRQ
1.29
Financials CLLS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CLLS
For 52 weeks
1.10 USD
3.00 USD
50 Day MA
1.38 USD
Shares Short Prior Month
340 330
200 Day MA
1.76 USD
Short Ratio
3.25
Shares Short
317 825
Short Percent
0.39 %
BeatStart